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T. E. Towheed
Department of Medicine, Queen’s University, Kingston, Ontario, CanadaThe objectives of this commentary are twofold: (1) to
identify which pharmacological agents used in the manage-
ment of osteoarthritis (OA) have published evidence in the
form of systematic reviews (SR) and meta-analyses (MA)
which supports their efficacy and/or toxicity, and (2) to
summarize the main findings from these studies.
An MA can be defined as an SR that employs statistical
methods to combine and summarize the results of several
studies. In evidence-based medicine, MA of randomized
controlled trials (RCTs) may well constitute the strongest
evidence for the value of an intervention. For example, a
commonly used grading scheme for evaluating the quality
of the evidence is one adapted from the US Agency for
Health Care Policy and Research. Grades 1A and 1B
evidence are the most robust and least biased sources of
evidence1. Grade 1A evidence is evidence obtained from
MA of RCTs. Grade 1B evidence is evidence obtained from
at least one RCT. There have been a total of 10 published
MA evaluating the following therapies for OA: conventional
NSAIDs, simple analgesics (e.g. acetaminophen), COX-2
selective NSAIDs, topical NSAIDs, topical capsaicin,
chondroitin sulfate and glucosamine2–12.
The meta-analyses of pharmacological therapies for OA
of the hip analysed 43 RCTs covering the time period of
1966 to August 19942,3. Main findings from these reviews
included the following: (1) the quality of the RCTs was
generally poor, (2) there was a lack of standardization of
case definition of OA and also a lack of standardization of
the outcome assessments, (3) NSAIDs were always better
than placebo, (4) it was rare to find differences in efficacy
between NSAIDs, and (5) there was a tendency for
indomethacin to be found more effective than comparator
NSAIDs, but also more toxic. Low dosages of naproxen
(<750 mg/day) and ibuprofen (<1600 mg/day) were less
efficacious than other NSAIDs.
The meta-analyses of pharmacological therapies for OA
of the knee involved two publications4,5. The first analysed
80 RCTs covering the time period of 1966 to August 19944.
The second analysed 16 RCTs covering the time period of
1966 to 19965. The main findings from these reviews
included the following: (1) evidence exists for the efficacy
of acetaminophen, topical capsaicin, intra-articular (IA)
steroids, IA hyaluronate, and NSAIDs in the treatment of
OA of the knee, (2) the quality of the RCTs was generally
poor, and (3) no substantial evidence is available related to836efficacy, to distinguish between equivalent recommended
doses of NSAIDs
Eccles et al.6 analysed three RCTs in an attempt to rank
the relative efficacy of acetaminophen and NSAIDs in the
treatment of OA. Their main finding was that NSAIDs
were slightly superior to acetaminophen in the outcomes of
pain at rest (effect size 0.35, 95% confidence interval,
0.17–0.53) and pain on motion (effect size 0.28, 95%
confidence interval, 0.08–0.48). However, there was no
significant difference in the time to walk 50 feet, or in the
quality of life improvements produced by the two therapies.
Moore et al.7 published an MA evaluating the efficacy
and safety of topical NSAIDs vs placebo. Twenty-five RCTs
evaluating subjects with ‘chronic pain conditions’ (including
OA) were analysed covering the time period of 1966 to
September 1996. The main findings were: (1) 8/13 RCTs
found that topical NSAIDs were superior to placebo with a
pooled relative risk (RR) for benefit of 2.0 (95% confidence
interval, 1.5–2.7). The number needed to treat (NNT) was
only 3.1 (95% confidence interval, 2.7–3.8), (2) two RCTs
compared topical NSAIDs to oral NSAIDs and found
equal efficacy, and (3) the safety of topical NSAIDs was
equivalent to placebo.
Zhang et al.8 published an MA evaluating the efficacy
and safety of topical capsaicin in a number of chronic
painful conditions, including OA. Three RCTs were
analysed covering the time period of 1980 to February
1994. The main findings were: (1) capsaicin cream was
better than placebo in providing pain relief in OA (odds ratio
of 4.36, 95% confidence interval of 2.8–6.9), (2) true
blinding was probably difficult to conduct with capsaicin.
The UK’s National Institute of Clinical Excellence (NICE)
published on their website an MA which evaluated the
efficacy and safety of the four available COX-2 selective
NSAIDs: celecoxib, rofecoxib, meloxicam, and etodolac9.
Fifty-three RCTs involving 61 731 patients with OA and RA
were analysed. The main findings of the NICE review were:
(1) COX-2 selective inhibitors have equivalent efficacy to
conventional NSAIDs, (2) COX-2 selective inhibitors are
effective in reducing the incidence of gastrointestinal (GI)
toxicity compared to conventional NSAIDs, (3) there is no
direct evidence to suggest that any one of the four COX-2
selective drugs is superior to another, (4) cost-effectiveness
of the COX-2 selective inhibitors is more likely to be
favorable in patients at high risk for gastrointestinal toxicity,
(5) COX-2 selective inhibitors are not recommended for
routine use in OA, and (6) COX-2 selective inhibitors are
recommended for use in patients at high risk for GI toxicity.Tel: 613-533-6896; Fax: 613-533-2189; E-mail:
tt5@post.queensu.ca
Osteoarthritis and Cartilage, Vol. 10, No. 11 837Leeb et al.10 published an MA evaluating the efficacy and
safety of chondroitin sulfate (CS) in OA. Seven RCTs
published between 1991 and 1998 were analysed. The
main findings of this review were: (1) CS was more effec-
tive than placebo in relieving the pain of OA with an effect
size of 0.9, (2) in terms of pain reduction, 65% of patients
taking CS will benefit more than from taking a placebo, (3)
the effect size for improvement in the Lequesne Index was
0.74, and (4) adverse effects were greater for the placebo
treated patients vs the CS treated patients.
McAlindon et al.11 published an MA evaluating the
efficacy of both glucosamine and CS in OA. Fifteen RCTs
were analysed covering the time period of 1966 to June
1999. The main findings of this review were: (1) there were
moderate effect sizes for glucosamine (0.44, with a 95%
confidence interval of 0.24–0.64) and large effect sizes for
CS (0.78, with a 95% confidence interval of 0.60–0.95), (2)
quality scores were generally low, with scores ranging from
12% to 55% of the maximum score, with a mean of 35%,
(4) the effects of both compounds are likely to be exagger-
ated given the methodological weaknesses inherent in the
RCTs (for example, lack of intention-to-treat analyses, lack
of allocation concealment and publication bias) and (3)
despite the methodological weaknesses, some degree of
efficacy does appear probable for both glucosamine and
CS.
Towheed et al.12 published an MA evaluating the efficacy
and toxicity of glucosamine compounds in OA. Sixteen
RCTs were analysed covering the time period of 1966 to
December 1999. The main findings of this review were: (1)
Glucosamine was superior to placebo in terms of pain
reduction (effect size 1.40, with a 95% confidence interval
of 0.65–2.14), (2) glucosamine was superior to placebo in
terms of improvements in the Lequesne Index (odds ratio of
2.04 with a 95% confidence interval of 1.38–3.02), (3)
glucosamine was superior to NSAIDs in terms of pain
reduction (effect size 0.86 with a 95% confidence interval of
0.58–1.14), and (4) glucosamine demonstrated an excel-
lent safety profile (only 14 of the nearly 1000 subjects
randomized to glucosamine were withdrawn because of
toxicity, and only 61 subjects reported any adverse
reactions).
In summary, SR and MA are useful techniques which
can be used to efficiently summarize and document the
relative value of pharmacological therapies in OA. This
methodology will continue to be very useful for the future
development of evidence-based guidelines for the
management of OA. The Cochrane Musculoskeletal Group
is taking an active leadership role in this regard with the
publication of systematic reviews of OA therapies in the
Cochrane Library.References
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